From April 2003 to September 2004, 59 ears from 55 patients received suction clearance and topical miconazole 2% (regimen 1) and in September 2004 to December 2005, 64 ears from 58 patients received the same combinations plus acidic drops [acetic acid 3% (v/ v) in 97% ethanol]. The mean age of patients treated with regimen 1 was 35.76+/-16 years and in regimen 2 was 37.98+/-15 years. Aspergilus sp and Candida sp were seen in 35 (59.3%) and 24 (40.7%) cases treated with regimen 1 and in 43 (67.2%) and 21 (32.8%) cases treated in regimen 2, respectively. Relapse occurred in 2 (3.4%) ears treated with regimen 1, but none in cases treated with regimen 2 (p=0.228). The findings reveal that there were no statistically significant differences between the two regimens and both may be used for the treatment of otomycosis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The efficacy and safety of tyrosine kinase inhibitors in the treatment of advanced or metastatic chordoma: a single-arm meta-analysis.
Neurosurg Rev
January 2025
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, 45# Changchun Street, Xicheng District, Beijing, China.
Chordoma is a rare malignant tumor with a higher incidence in males than in females. There is an increasing number of clinical studies related to tyrosine kinase inhibitors (TKIs), yet the efficacy and safety of different drugs vary. In this single-arm meta-analysis evaluating the efficacy and safety of TKIs for chordoma treatment, 12 studies involving 365 patients were analyzed.
View Article and Find Full Text PDFThe efficacy and safety of suvemcitug, envafolimab, and FOLFIRI in microsatellite-stable or mismatch repair-proficient colorectal cancer: preliminary results of a phase 2 study.
Int J Colorectal Dis
January 2025
Internal Medicine, Jilin Cancer Hospital, Changchun, China.
Purpose: This phase II study is designed to evaluate the combination therapy involving suvemcitug and envafolimab with FOLFIRI in microsatellite-stable or mismatch repair-proficient (MSS/pMMR) colorectal cancer (CRC) in the second-line treatment setting.
Methods: This study is a non-randomized, open-label prospective study comprising multiple cohorts (NCT05148195). Here, we only report the data from the CRC cohort.
Speech therapy for exercise-induced laryngeal obstruction.
Eur Arch Otorhinolaryngol
January 2025
Department of Pediatric and Adolescent Medicine, Haukeland University Hospital, Bergen, Norway.
Introduction: Exercise- Induced Laryngeal Obstruction (EILO) can lead to disabling exercise related dyspnea and hamper participation in physical activity. In this study, we aimed to investigate the effects of a standardized speech therapy protocol as treatment for EILO.
Methods: Patients diagnosed with EILO at our institution were invited to participate.
Tailoring Exercise Prescription for Effective Diabetes Glucose Management.
J Clin Endocrinol Metab
January 2025
Department of Kinesiology and Health, Rutgers University, New Brunswick, NJ 08901, USA.
Context: Physical activity, exercise, or both are a staple of lifestyle management approaches both for type 1 diabetes mellitus (T1DM) and type 2 diabetes (T2DM). While the current literature supports both physical activity and exercise for improving glycemic control, reducing cardiovascular risk, maintaining proper weight, and enhancing overall well-being, the optimal prescription regimen remains debated.
Evidence Acquisition: We searched PubMed and Google Scholar databases for relevant studies on exercise, insulin sensitivity, and glycemic control in people with T1DM and T2DM.
Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the 'RTL' (regional Tuscan lymphoma network).
Leuk Lymphoma
January 2025
Unit of Hematology, Azienda Ospedaliera Universitaria Senese and University of Siena, Siena, Italy.
Treatment strategies for early stage diffuse large B-cell lymphoma (ES-DLBCL) include R-CHOP, with a similar schedule to that used in advanced stage, or a reduced number of cycles followed by radiation therapy (RT). We retrospectively analyzed 179 ES-DLBCL patients, managed according to the clinical practice. Treatment regimens include chemoimmunotherapy 4-6 cycles +/- RT as consolidation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!